A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Azacitidine Followed by Bridging Transplantation in Patients with High-Risk Myelodysplastic Neoplasms with Increased Blasts 2 (MDS-IB2)
Newly diagnosed MDS confirmed by morphological and immunophenotypic analysis of bone marrow；
Age ≥18 years, any gender；
Bone marrow blasts ≥10%；
IPSS-R score >4.5；
Extramedullary disease involvement；
Hypersensitivity to any study drugs；
Clinically significant hepatic/renal dysfunction exceeding inclusion thresholds；
Severe cardiac disease, including congestive heart failure, myocardial infarction, and cardiac insufficiency;
Yehui Tan
Lead sponsor
The First Hospital of Jilin University
Sponsor institution